Synergic effects of cancer stem cells markers, CD44 and embryonic stem cell transcription factor Nanog, on bladder cancer prognosis.

Synergic effects of cancer stem cells markers, CD44 and embryonic stem cell transcription factor Nanog, on bladder cancer prognosis. Br J Biomed Sci. 2019 Nov 13; Authors: Siddiqui Z, Srivastava AN, Sankhwar SN, Dalela D, Singh V, Zaidi N, Fatima N, Bano I, Anjum S Abstract Purpose of the study: Therapy that targets cancer stem cells has the potential to eradicate cancer cells and prevent tumour recurrence. Therefore, we hypothesised the combined prognostic significance of stem cell markers CD44 (prevalent in basal layer of urothelial carcinoma) and Nanog (embryonic stem cell transcription factor) in bladder cancer.Material and Methods: CD44 and Nanog expression were determined by immunohistochemistry in 112 bladder cancer cases of which 79 were non-muscle invasive and 33 muscle invasive.Results: A significant correlation was found between CD44 and Nanog expression (r= 0.41, p
Source: British Journal of Biomedical Science - Category: Laboratory Medicine Tags: Br J Biomed Sci Source Type: research

Related Links:

ConclusionOur study demonstrated a significant correlation between Nectin-4 expression and tumor grade as well as stages (p 
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
Discussion MDSCs violently emerge in pathological conditions in an attempt to limit potentially harmful immune and inflammatory responses. Mechanisms supporting their expansion and survival are deeply investigated in cancer, in the perspective to reactivate specific antitumor responses and prevent their contribution to disease evolution. These findings will likely contribute to improve the targeting of MDSCs in anticancer immunotherapies, either alone or in combination with immune checkpoint inhibitors. New evidence indicates that the expansion of myeloid cell differentiation in pathology is subject to fine-tuning, as its...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Yong Zhao1, Peijuan Liu1, Zhiqian Xin1, Changhong Shi1, Yinlan Bai2, Xiuxuan Sun3, Ya Zhao1, Xiaoya Wang1,4, Li Liu1,5, Xuan Zhao1,4, Zhinan Chen3* and Hai Zhang1,6* 1Laboratory Animal Center, Air Force Medical University, Xi’an, China 2Department of Microbiology, Air Force Medical University, Xi’an, China 3Department of Cell Biology, National Translational Science Center for Molecular Medicine, Air Force Medical University, Xi’an, China 4College of Veterinary Medicine, Northwest A&F University, Yangling, China 5Key Laboratory for Space Bioscience and Biotechnology, School of Life Sciences, Nor...
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
Conclusions Several model systems are now available to characterize the MSC-tumour interplay in the TME. These offer early promise in establishing robust preclinical platforms for the identification of crucial molecular pathways and for the assessment of clinical efficacy of novel drugs to inhibit cancer development and progression. However, selection of the right model for a given study should be shaped on the purpose, and should also consider fixed biological, biochemical, and biophysical parameters according to the specific tumour type. Finally, in order to get reliable and useful results to be translated to the clinic...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Chiu-Min Lin1†, Ching-Fang Yu2,3†, Hsueh-Ya Huang1,4, Fang-Hsin Chen2,3,5, Ji-Hong Hong2,3,5 and Chi-Shiun Chiang1,6,7* 1Department of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu, Taiwan 2Department of Radiation Oncology, Chang Gung Memorial Hospital Linkou Branch, Taoyuan, Taiwan 3Radiation Biology Research Center, Institute for Radiological Research, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan 4Education &Medical Research National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan 5Department of Medical Imaging an...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
This study aimed to investigate whether combining anti-PD-L1 Atezolizumab with BEV may have a synergistic effect and enhance the efficacy of both treatments in cisplatin resistant epithelial ovarian cancer (CREOC). We retrospectively analyzed 124 epithelial ovarian cancer (EOC) patients from Gynecologic Oncology Department of Tianjin Cancer Hospital between January 2013 and June 2018, who all were diagnosed with cisplatin resistance due to progressing
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Eleonora A. Braga1*†, Marina V. Fridman2†, Vitaly I. Loginov1,3, Alexey A. Dmitriev4 and Sergey G. Morozov1 1Institute of General Pathology and Pathophysiology, Moscow, Russia 2Vavilov Institute of General Genetics, Russian Academy of Sciences, Moscow, Russia 3Research Center of Medical Genetics, Moscow, Russia 4Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia Clear cell renal cell carcinoma (ccRCC) is the third most common urological cancer, and it has the highest mortality rate. The increasing drug resistance of metastatic ccRCC has resulted in the search f...
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
Abstract Doublecortin-like kinase 1 (DCLK1) has been characterized as a novel potential cancer stem cell (CSC) marker in several types of cancer. It is considered as one of the most specific markers for distinguishing colorectal CSCs from normal stem cells. Yet, there are limited reports on the role of DCLK1 as a putative CSC marker in bladder cancer. Using immunohistochemistry, DCLK1 expression was examined in a well-defined tissue microarray series of 472 bladder cancer tissues. The association between DCLK1 protein expression and clinicopathological features, as well as survival outcomes, was assessed. Our find...
Source: Experimental and Molecular Pathology - Category: Pathology Authors: Tags: Exp Mol Pathol Source Type: research
In conclusion, we showed hypermethylation of CpGs as a novel mechanism of action for DNMTi agents and identified 638 hypermethylated molecular targets (CpGs) common to decitabine and azacytidine therapy. These novel results suggest that hypermethylation of CpGs should be considered when predicting the DNMTi responses and side effects in cancer patients. Introduction DNA methyltransferase inhibitors (DNMTi) are widely used as chemical tools for hypomethylating the genome, with an aim to understand the role of DNA methylation in multiple processes (e.g., X-chromosome inactivation and DNA imprinting) and as an anti-ca...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
This study was carried out in accordance with the recommendations of the Case Western Reserve University IACUC committee. The protocol was approved by the Case Western Reserve University IACUC committee. Author Contributions LRD and DW helped design research studies, analyze data and write the manuscript. ZL, RL, and ND conducted experiments, acquired and analyzed data, and assisted with manuscript preparation. LDM conducted experiments and analyzed data. FC assisted with research design. Funding This work was supported by the NIH P30CA043703, K1CA113838, and R01DK081395. Conflict of Interest Statement The authors de...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
More News: Biomedical Science | Bladder Cancer | Cancer | Cancer & Oncology | Carcinoma | Laboratory Medicine | Nanotechnology | Science | Stem Cell Therapy | Stem Cells | Study | UK Health